BIX-02565

Description	BIX 02565 is an attractive candidate for use in vitro and in vivo to explore the role of RSK as a target for the treatment heart failure. Besides, BIX 02565 is a multikinase inhibitor, including LRRK2, RET, CLK2, FLT3 and PDGFR. At this point, we returned to the panel of 20 kinases used for optimization to obtain a more accurate picture of kinase selectivity for 24. Six kinases furnished an IC50 less than 1 lM: the live that had shown greater than 80% inhibition in the selectivity count, and PDGFRa which had shown 71% inhibition. Additionally, compound 24 was more than 100-fold selective relative to RSK for the kinase panel, with the exception of LRRK2 and PRKD1, for which compound 24 showed 16- and 35-fold selectivity, respectively. We then expanded the kinase panel to include over 200 additional unique kinases. We were pleased to and that 24 had an IC50 of less than 1 lM for only four other family members (PRKD2, PRKD3, RET, and FLT3). These results con?rmed the power of the selectiv
Pathways	PI3K/Akt/mTOR MAPK Pathway
Targets	RSK

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.